Mage P, Coindre J M, Goussot J F, Ballanger P, Lamarche P
Ann Urol (Paris). 1985;19(3):203-6.
Bone pains observed in patients undergoing estrogen therapy, and presenting with osteoblastic metastases from prostatic cancer are usually related to unsuccessful treatment. In some patients, these pains may result from osteomalacia--ie incomplete mineralization of the new bone--because of the drainage of calcium by the osteoblastic metastases. A clinical, biological and histomorphometric study of bone specimens without decalcification was conducted in ten patients with osteoblastic disease secondary to prostatic carcinoma, who were under estrogen therapy, and for whom a change of therapy was contemplated. The study reports three cases of osteomalacia. Their bone pains were more intense, more diffuse and more permanent than those registered by patients without osteomalacia. All three had had previous fractures of the neck of the femur and a low urinary and serum calcium and phosphorus content. The discovery of osteomalacia by histomorphometric study is important because it allows effective, etiological treatment of the bone pains in these patients.
接受雌激素治疗且伴有前列腺癌成骨转移的患者出现骨痛，通常与治疗失败有关。在一些患者中，这些疼痛可能是由于成骨转移导致钙流失，进而引起骨软化症，即新骨矿化不完全。对10例接受雌激素治疗且考虑更换治疗方案的前列腺癌继发成骨疾病患者的未脱钙骨标本进行了临床、生物学和组织形态计量学研究。该研究报告了3例骨软化症病例。他们的骨痛比没有骨软化症的患者更剧烈、更弥漫且更持久。这3例患者均曾有股骨颈骨折史，尿钙和血磷含量较低。通过组织形态计量学研究发现骨软化症很重要，因为这能对这些患者的骨痛进行有效的病因治疗。
